Patents Examined by Agnieszka Boesen
  • Patent number: 11905320
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: May 26, 2023
    Date of Patent: February 20, 2024
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11896662
    Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: February 13, 2024
    Assignee: Novavax, Inc.
    Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
  • Patent number: 11865080
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: January 9, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11866463
    Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 9, 2024
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Luke T. Daum, Gerald W. Fischer, Clara J. Sei
  • Patent number: 11857562
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: January 2, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11851467
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 26, 2023
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11845787
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: December 19, 2023
    Assignees: The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
    Inventors: David Weiner, Megan Wise
  • Patent number: 11839650
    Abstract: The present application generally relates to the development of a universal influenza vaccine, or production of antibodies, capable of providing broad protection against various strains of the flu, using an informational spectrum method (ISM) to identify the common structural characteristics of influenza antigens.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: December 12, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Veljko Veljkovic, Slobodan Paessler
  • Patent number: 11834649
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: December 5, 2023
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • Patent number: 11826416
    Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: November 28, 2023
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason L. Dehart
  • Patent number: 11827668
    Abstract: The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: November 28, 2023
    Assignee: SANOFI PASTEUR INC.
    Inventors: Tod Dwayne Strugnell, Guadalupe Cortes-Garcia, Tim Alefantis
  • Patent number: 11820794
    Abstract: Disclosed herein include methods, compositions, and kits suitable for robust and tunable control of payload gene expression. Some embodiments provide rationally designed circuits, including miRNA-level and/or protein-level incoherent feed-forward loop circuits, that maintain the expression of a payload at an efficacious level. The circuit can comprise a promoter operably linked to a polynucleotide encoding a fusion protein comprising a payload protein, a protease, and one or more self-cleaving peptide sequences. The payload protein can comprise a degron and a cut site the protease is capable of cutting to expose the degron. The circuit can comprise a promoter operably linked to a polynucleotide comprising a payload gene, a silencer effector cassette, and one or more silencer effector binding sequences.
    Type: Grant
    Filed: November 21, 2020
    Date of Patent: November 21, 2023
    Assignee: California Institute of Technology
    Inventors: Michael J. Flynn, Michael B. Elowitz, Acacia Hori, Viviana Gradinaru
  • Patent number: 11813323
    Abstract: The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: November 14, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Philip Dormitzer
  • Patent number: 11802273
    Abstract: The disclosure provides for an isolated recombinant influenza virus having at least one of: a PA gene segment encoding PA with a residue at position 443 that is not arginine, a PB1 gene segment encoding PB1 with a residue at position 737 that is not lysine, a PB2 gene segment encoding PB2 with a residue at position 25 that is not valine or a residue at position 712 that is not glutamic acid, a NS gene segment encoding a NS1 with a residue at position 167 that is not proline, a HA gene segment encoding a HA with a residue at position 380 that is not threonine, or any combination thereof, and methods of making and using the virus.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: October 31, 2023
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Yoshihiro Kawaoka, Satoshi Fukuyama, Shinji Watanabe
  • Patent number: 11795478
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Grant
    Filed: May 11, 2022
    Date of Patent: October 24, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
  • Patent number: 11786590
    Abstract: The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: October 17, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Benjamin Petsch
  • Patent number: 11781112
    Abstract: The disclosed method provides a novel approach of generating antigen-specific Immunological Memory in a subject which consists primarily of extracting and purifying monocytes, naive T and B lymphocytes from a subject and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are generated with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject. In embodiments, one will see a vaccine approach wherein said vaccine excludes the inoculation of attenuated or killed whole pathogens, where inoculation of said vaccine does not illicit an immune response upon inoculation, and where said vaccine excludes chemicals such as thimerosal, formaldehyde, and aluminum which is all shunned by anti-vaccinators.
    Type: Grant
    Filed: March 4, 2017
    Date of Patent: October 10, 2023
    Inventor: Kareem Thomas Robinson
  • Patent number: 11771758
    Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: October 3, 2023
    Assignee: Helix Nanotechnologies, Inc.
    Inventors: Kyle Backman, Nikhil Dhar, Nikolai Eroshenko, Taylor Gill, Kemo Jammeh, Marianna Keaveney, Justin Quinn, Hannu Rajaniemi, Everett Webster
  • Patent number: 11771760
    Abstract: The present invention relates to a fusion protein having formula (I) X1?Y?X2??(I), wherein X1 and X2 comprise each four to six allergen fragments or variants thereof fused to each other, wherein said allergen fragments are derived from at least two allergens of the genus Dermatophagoides, and wherein Y is a carrier protein.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: October 3, 2023
    Assignee: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.
    Inventors: Rudolf Valenta, Mirela Curin, Kuan-Wei Chen, Susanne Vrtala
  • Patent number: 11771754
    Abstract: The present invention relates to a mutated HPV18 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (for example, HPV18 and HPV45, or HPV18, HPV45 and HPV59), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: October 3, 2023
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Shuo Song, Maozhou He, Jingjie Shi, Ying Gu, Ningshao Xia